ProShares UltraShort Health Care (RXD)
| Assets | $1.33M |
| Expense Ratio | 0.95% |
| PE Ratio | n/a |
| Shares Out | 130,430 |
| Dividend (ttm) | $0.52 |
| Dividend Yield | 4.82% |
| Ex-Dividend Date | Dec 23, 2024 |
| Payout Ratio | n/a |
| 1-Year Return | +2.31% |
| Volume | 11,587 |
| Open | 10.54 |
| Previous Close | 10.46 |
| Day's Range | 10.53 - 10.78 |
| 52-Week Low | 9.11 |
| 52-Week High | 12.35 |
| Beta | -1.17 |
| Holdings | 7 |
| Inception Date | Jan 30, 2007 |
About RXD
Fund Home PageThe ProShares UltraShort Health Care (RXD) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund provides -2x exposure to a market-cap-weighted index of US health care companies. RXD was launched on Jan 30, 2007 and is issued by ProShares.
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 23, 2024 | $0.10129 | Dec 31, 2024 |
| Sep 25, 2024 | $0.10006 | Oct 2, 2024 |
| Jun 26, 2024 | $0.19221 | Jul 3, 2024 |
| Mar 20, 2024 | $0.12546 | Mar 27, 2024 |
| Dec 20, 2023 | $0.1218 | Dec 28, 2023 |
| Sep 20, 2023 | $0.09419 | Sep 27, 2023 |
News
ProShares and ProFunds Announce Benchmark Changes for 53 Geared Sector Funds
BETHESDA, Md.--(BUSINESS WIRE)--ProShares and ProFunds, premier providers of leveraged and inverse funds, announced plans to change the underlying indices for a combined 53 sector ETFs and mutual fu...
Purchase Levels Of 31 Short ETFs Signal Bear Market Bottom (Technical Analysis)
We are bearish on all American bear market ETFs. Measuring the purchase levels of short ETFs replaces the old, odd lot and total short selling indicators so popular in the 1960s, 70s and 80s.
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Healthcare: A Wide Choice Of Large And Well-Established Companies
The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets...